Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alberto Sobrero

Showing results (51-60 of 80) with videos related to

Pageof 8
Sort By:
Arthritis Care & Research|April 21, 2025
Development, Usability, and Validity Evidence of a Rheumatology Telehealth Feedback FormLisa Zickuhr, Alberto Sobrero, Daniel Albert, et al.
Investigational New Drugs|May 13, 2010
Phase II study of sunitinib as second-line treatment for advanced gastric cancerYung-Jue Bang, Yoon-Koo Kang, Won K Kang, et al.
European Journal of Cancer (Oxford, England : 1990)|February 9, 2023
Reliability of patient-reported toxicities during adjuvant chemotherapyMalvina Cremante, Alessandro Pastorino, Marta Ponzano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 6, 2018
FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant TrialAlberto Sobrero, Sara Lonardi, Gerardo Rosati, et al.
Lancet (London, England)|November 27, 2012
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trialAxel Grothey, Eric Van Cutsem, Alberto Sobrero, et al.
The Lancet. Oncology|July 18, 2015
Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trialJosep Tabernero, Heinz-Josef Lenz, Salvatore Siena, et al.
The Oncologist|March 31, 2025
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer: safety analysis of FRESCO-2Cathy Eng, Arvind Dasari, Sara Lonardi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 28, 2013
Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal cancer: the RESPECT trialJosep Tabernero, Rocio Garcia-Carbonero, James Cassidy, et al.
JAMA Oncology|February 14, 2020
Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical TrialFausto Petrelli, Roberto Labianca, Alberto Zaniboni, et al.
European Journal of Cancer (Oxford, England : 1990)|May 29, 2024
Standardizing data collection in adjuvant colon cancer trials: A consensus project from the IDEA and ACCENT international consortia and national expertsJulien Taieb, Debora Basile, Jenny Seligmann, et al.
Pageof 8

Showing results (51-60 of 80) with videos related to

Sort By:
Pageof 8
Arthritis Care & Research|April 21, 2025
Development, Usability, and Validity Evidence of a Rheumatology Telehealth Feedback FormLisa Zickuhr, Alberto Sobrero, Daniel Albert, et al.
Investigational New Drugs|May 13, 2010
Phase II study of sunitinib as second-line treatment for advanced gastric cancerYung-Jue Bang, Yoon-Koo Kang, Won K Kang, et al.
European Journal of Cancer (Oxford, England : 1990)|February 9, 2023
Reliability of patient-reported toxicities during adjuvant chemotherapyMalvina Cremante, Alessandro Pastorino, Marta Ponzano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 6, 2018
FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant TrialAlberto Sobrero, Sara Lonardi, Gerardo Rosati, et al.
Lancet (London, England)|November 27, 2012
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trialAxel Grothey, Eric Van Cutsem, Alberto Sobrero, et al.
The Lancet. Oncology|July 18, 2015
Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trialJosep Tabernero, Heinz-Josef Lenz, Salvatore Siena, et al.
The Oncologist|March 31, 2025
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer: safety analysis of FRESCO-2Cathy Eng, Arvind Dasari, Sara Lonardi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 28, 2013
Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal cancer: the RESPECT trialJosep Tabernero, Rocio Garcia-Carbonero, James Cassidy, et al.
JAMA Oncology|February 14, 2020
Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical TrialFausto Petrelli, Roberto Labianca, Alberto Zaniboni, et al.
European Journal of Cancer (Oxford, England : 1990)|May 29, 2024
Standardizing data collection in adjuvant colon cancer trials: A consensus project from the IDEA and ACCENT international consortia and national expertsJulien Taieb, Debora Basile, Jenny Seligmann, et al.
Pageof 8